Receptor Tyrosine Protein Kinase ERBB 3 Market Size & Outlook, 2025-2033

Market Overview

The global receptor tyrosine protein kinase ERBB 3 market size was valued at USD 11.36 Billion in 2024 and is projected to grow from USD 12.08 Billion in 2025 to reach USD 19.69 Billion by 2033, growing at a CAGR of 6.3% during the forecast period (2025–2033). 

Several key factors have contributed to the recent growth of the market for Receptor Tyrosine Protein Kinase ERBB 3. The rising global prevalence of cancer has increased the demand for innovative tyrosine-protein kinase therapies, propelling the market growth. Additionally, the rising awareness of cancer diagnosis and treatment in underdeveloped and developing countries has accelerated market growth. Furthermore, the introduction of advanced tyrosine kinase inhibitors and technological advancements in developing safer and more effective products have also played a critical role in the market's growth.

Receptor tyrosine-protein kinase ERBB-3, also known as HER3 (human epidermal growth factor receptor 3), is a membrane-bound protein encoded by the ERBB3 gene in humans. ErbB3 is a member of the epidermal growth factor receptor (EGFR/ERBB) family of receptor tyrosine kinases. Unlike other ERBB receptors, ErbB3 has impaired kinase activity and must form heterodimers with other ERBB family members, particularly ErbB2, to be activated.

The ErbB2-ErbB3 heterodimer is considered the most potent of the ERBB dimers, as it can activate multiple signaling pathways, including MAPK, PI3K/Akt, and PLCγ. ErbB3 plays a crucial role in the pathogenesis of many cancers, despite the initial perception that it was kinase-dead. Somatic ERBB3 mutations are frequently encountered in various human cancers, and its dysregulation, along with cooperation with other receptor tyrosine kinases, enhances its role in tumorigenesis and drug resistance. As a result, ErbB3 is increasingly considered an important therapeutic target in cancer treatment.

Highlights

• Monoclonal Antibody dominates the type segment.
• Flow Cytometry dominates the application segment.
• North America is the highest shareholder in the global market

To get more insights about this report Download Free Sample Report

Market Dynamics

Global Receptor Tyrosine Protein Kinase Erbb 3 Market Drivers

Increasing Prevalence of Cancer

The increasing prevalence of cancer significantly drives the demand for the global Receptor Tyrosine Protein Kinase ERBB 3 Market. ERBB 3, also known as HER3, is a protein intricately linked to cancer progression. As the world's second leading cause of death, cancer accounted for an estimated 19.3 million new cases and nearly 10 million deaths in 2020, underscoring the urgent need for innovative treatments. Overexpression of ERBB 3 is associated with aggressive breast, lung, colorectal, and ovarian cancers, often leading to poor patient outcomes.

ERBB 3 plays a crucial role in cancer cell survival, proliferation, and resistance to therapy, making it a promising target for new treatments. This has spurred the development of targeted therapies, including monoclonal antibodies and small molecule inhibitors specifically aimed at ERBB 3. The market is driven by the growing understanding of ERBB 3's role in cancer and the critical need for effective treatments amid the rising global cancer burden.

Global Receptor Tyrosine Protein Kinase Erbb 3 Market Restraint

Competition from Alternative Therapies

The Receptor Tyrosine Protein Kinase ERBB 3 Market faces significant challenges from alternative therapies. Despite the promise of ERBB 3-targeted treatments, they contend with well-established cancer therapies targeting different pathways. Notably, HER2 inhibitors like trastuzumab (Herceptin) and pertuzumab (Perjeta) have demonstrated substantial clinical benefits in HER2-positive breast and gastric cancers, with Herceptin alone generating $7.4 billion in global sales by 2020.

Additionally, the advent of immune checkpoint inhibitors, such as pembrolizumab (Keytruda) and nivolumab (Opdivo), has revolutionized cancer treatment, with the global market for these inhibitors projected to reach $63.9 billion by 2028, growing at a CAGR of 13.7%. Furthermore, novel therapies targeting signaling pathways like BRAF, MEK, and PI3K/AKT/mTOR add to the competitive landscape. These alternatives present formidable competition, potentially limiting the market penetration and growth of ERBB 3-targeted therapies. 

Global Receptor Tyrosine Protein Kinase Erbb 3 Market Opportunities

Technological Advancements

Technological advancements present significant opportunities for growth in the Global Receptor Tyrosine Protein Kinase ERBB 3 Market. With deeper insights into cancer biology and molecular mechanisms, new technologies are enhancing the targeting and delivery of ERBB 3-targeted therapies. Notably, antibody-drug conjugates (ADCs) like patritumab deruxtecan and disitamab vedotin are designed to selectively deliver cytotoxic drugs to cancer cells expressing ERBB 3. Improved biomarker identification and companion diagnostics have refined patient selection for ERBB 3-targeted therapies, leading to better treatment outcomes and cost savings.

The global companion diagnostics market is projected to reach $8.6 billion by 2027, driven by the growing adoption of personalized medicine in cancer care. Additionally, novel drug delivery systems such as nanoparticles and liposomes offer the potential to enhance efficacy and reduce side effects of ERBB 3-targeted therapies. These technological advancements are poised to transform targeted cancer therapies, providing more effective and personalized treatment options for patients in the Receptor Tyrosine Protein Kinase ERBB 3 Market.

Regional Analysis

Based on region, the global market is bifurcated into North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa. 

North America Dominates the Global Market

North America is the most significant global market shareholder and is expected to expand substantially during the forecast period. North America holds a significant share of the global Receptor Tyrosine Protein Kinase ERBB 3 market and is projected to expand substantially during the forecast period. This dominance is attributed to several key factors, including a well-established pharmaceutical industry, robust research and development initiatives, and a favorable regulatory environment. The United States, in particular, leads this market within the region. A notable driver of this dominance is the high prevalence of breast cancer, with an estimated 287,850 new cases in 2022. ERBB 3 plays a critical role in the development and progression of breast cancer, creating a substantial demand for ERBB 3-targeted therapies.

Furthermore, the United States Food and Drug Administration (FDA) has approved several ERBB 3-targeted therapies for various cancer indications, further solidifying the region's leadership. Notable approvals include Enhertu (trastuzumab deruxtecan) for metastatic breast cancer and Padcev (enfortumab vedotin-ejfv) for advanced bladder cancer. These approvals have not only provided effective treatment options but also paved the way for further research and development in ERBB 3-targeted therapies.

Moreover, the presence of leading pharmaceutical companies such as Genentech, AstraZeneca, and Daiichi Sankyo, which are actively involved in the development of these therapies, is another significant factor contributing to the region's market dominance. These companies are at the forefront of innovation, continually advancing the field through extensive research and clinical trials. Thus, North America's leadership in the global Receptor Tyrosine Protein Kinase ERBB 3 market is driven by a combination of high disease prevalence, regulatory support, and the active involvement of leading pharmaceutical companies in developing cutting-edge therapies.

Europe is projected to be the fastest-growing region in the Global Receptor Tyrosine Protein Kinase ERBB 3 Market during the forecast period, driven by a robust focus on cancer research, supportive regulatory frameworks, and the presence of leading pharmaceutical companies. The region accounts for approximately 23.4% of global cancer cases and 20.3% of cancer-related deaths, underscoring the urgent need for innovative therapies. The European Medicines Agency (EMA) has approved several ERBB 3-targeted therapies, such as Enhertu (trastuzumab deruxtecan) for metastatic breast cancer and Padcev (enfortumab vedotin-ejfv) for advanced bladder cancer, ensuring these treatments are accessible to European patients.

Europe is home to prominent pharmaceutical companies like Roche, Novartis, and Sanofi, which are at the forefront of developing ERBB 3-targeted therapies and other cancer treatments. The region's strong emphasis on collaborative research initiatives and partnerships among academic institutions, pharmaceutical companies, and government organizations has fostered a conducive environment for the advancement of ERBB 3-targeted therapies. This synergy is further bolstered by significant investments in R&D and a favorable regulatory landscape, positioning Europe as a pivotal player in the global ERBB 3 market.

Segmental Analysis

The global market is bifurcated into type and application.

Based on type, the market is segmented into Monoclonal Antibody and Polyclonal Antibody.

Monoclonal Antibody dominates the type segment. The increasing demand for Monoclonal Antibodies in the Receptor Tyrosine Protein Kinase ERBB 3 market is due to their high specificity and affinity for the target protein, ERBB 3. Cloning a single B cell produces monoclonal antibodies, which are homogeneous populations of antibodies that recognize a specific epitope on the ERBB 3 protein. This specificity makes them ideal for a variety of applications, including flow cytometry, ELISA, Western Blot, immunoprecipitation, and immunofluorescence. Furthermore, the growing use of monoclonal antibodies in cancer research and treatment has increased demand in the Receptor Tyrosine Protein Kinase ERBB 3 market. ERBB 3 is overexpressed in a variety of cancers, including non-small cell carcinoma, solid tumors, melanoma, and colorectal cancer, making it an attractive target for cancer treatment. Monoclonal antibodies against ERBB 3 have demonstrated the potential to inhibit tumor growth and improve patient outcomes.

Based on application, the market is segmented into Flow Cytometry, ELISA, Western Blot, Immunoprecipitation, Immunofluorescence, and Other.

Flow Cytometry dominates the application segment. Flow Cytometry is in high demand in the Receptor Tyrosine Protein Kinase ERBB 3 market due to its ability to quickly and accurately analyze ERBB 3 expression on cell surfaces. Flow Cytometry can measure multiple parameters on a single cell, making it an effective tool for studying ERBB 3 expression and distribution across different cell types. This technique is commonly used in cancer research to evaluate the expression of ERBB 3 in tumor cells and its impact on disease progression and treatment response. The demand for Flow Cytometry in the Receptor Tyrosine Protein Kinase ERBB 3 market has increased due to its growing use in diagnostic applications. ERBB 3 is a promising biomarker for cancers such as non-small cell carcinoma, solid tumors, melanoma, and colorectal cancer. Flow cytometry-based assays can aid in the early detection and monitoring of these cancers by quantifying the expression of ERBB 3 in patient samples.

List of key players in Receptor Tyrosine Protein Kinase ERBB 3 Market

1. AstraZeneca Plc (UK)
2. AVEO Pharmaceuticals, Inc. (US)
3. Etubics Corporation (South Korea)
4. F. Hoffmann-La Roche Ltd. (Switzerland)
5. GamaMabs Pharma S.A. (France)
6. Merck KGaA (Germany)
7. Pfizer Inc. (US)
8. Novartis International AG (Switzerland)
9. Bayer AG (Germany)
10. BeiGene, Ltd. (China)
11. Seagen Inc. (US)
12. Exelixis, Inc. (US)
13. Mirati Therapeutics, Inc. (US)
14. Pyxis Oncology, Inc. (US)
15. Herceptin Biosimilar Manufacturers

To get more findings about this report Download Market Share

Recent Developments

• March 2024- Daiichi Sankyo Company, a global pharmaceutical company, announced positive results from a Phase 3 clinical trial evaluating its ERBB 3-targeted antibody-drug conjugate (ADC), patritumab deruxtecan (U3-1402), for the treatment of metastatic non-small cell lung cancer (NSCLC).
• October 2023- AstraZeneca, a leading biopharmaceutical company, announced the initiation of a global Phase 2/3 clinical trial for its ERBB 3-targeted monoclonal antibody, seribantumab, in combination with its antibody-drug conjugate, trastuzumab deruxtecan (Enhertu), for the treatment of metastatic breast cancer.